durvalumab – Talk Bio

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

2 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates

FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer, Marking First Systemic Immunotherapy for LS-SCLC

12 months ago talkbio0Tagged ADRIATIC, Approved, Breakthrough Therapy, durvalumab, Identifier, Imfinzi, Limited-stage, LS-SCLC, Phase 3 Clinical Trials, Priority Review, Systemic Immunotherapy, United States Food and Drug Administration

Imfinzi (durvalumab), Limited-stage small cell lung cancer (LS-SCLC), FDA approval, Systemic immunotherapy, ADRIATIC Phase III trial, Breakthrough Therapy Designation, Priority Review

ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

1 year ago talkbio0Tagged Advanced phase, AstraZeneca, durvalumab, ESMO24, Imfinzi, Imjudo, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma, Overall Survival, tremelimumab

AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

1 year ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial

FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery

1 year ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Immunologic Adjuvants, Malignant neoplasm of lung, Neoadjuvant Therapy, Non-Small Cell Lung Carcinoma, Surgery specialty, United States Food and Drug Administration

FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC

FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment

1 year ago talkbio0Tagged durvalumab, Immunotherapy, Malignant neoplasm of endometrium, pembrolizumab, Pharmacotherapy, United States Food and Drug Administration

FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy

AstraZeneca’s IMFINZI Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Endometrial Cancer

1 year ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Malignant neoplasm of endometrium, Mismatch Repair Deficiency, Pharmacotherapy, United States Food and Drug Administration

IMFINZI, durvalumab, endometrial cancer, mismatch repair deficient, chemotherapy, AstraZeneca, FDA approval

AstraZeneca’s Imfinzi Demonstrates Survival Benefit in Limited-Stage Small Cell Lung Cancer Study

2 years ago talkbio0Tagged ADRIATIC, AstraZeneca, durvalumab, Imfinzi, Immunotherapy, Limited-stage SCLC, Overall Survival, Phase 3 Clinical Trials, Progression-Free Survival, Small cell carcinoma of lung

AstraZeneca, Imfinzi (durvalumab), Small Cell Lung Cancer (SCLC), Limited-stage SCLC, ADRIATIC Phase III study, Overall Survival (OS), Progression-Free Survival (PFS), Immunotherapy